CAR-T cells: Early successes in blood cancer and challenges in solid tumors.
10.1016/j.apsb.2020.10.020
- Author:
Hassan DANA
1
;
Ghanbar Mahmoodi CHALBATANI
2
;
Seyed Amir JALALI
3
;
Hamid Reza MIRZAEI
2
;
Stephan A GRUPP
4
;
Eloah Rabello SUAREZ
5
;
Catarina RAPÔSO
6
;
Thomas J WEBSTER
7
Author Information
1. Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran 13145-158, Iran.
2. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran.
3. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717434, Iran.
4. Division of Oncology, Department of Pediatrics, the Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
5. Center for Natural and Human Sciences, Federal University of ABC, Santo André, SP 09210-580, Brazil.
6. Faculty of Pharmaceutical Sciences, State University of Campinas (UNICAMP), Campinas, SP 13083-871, Brazil.
7. Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
- Publication Type:Review
- Keywords:
Chimeric antigen receptor (CAR);
Genetic engineering;
Immunotherapy;
T cell therapy
- From:
Acta Pharmaceutica Sinica B
2021;11(5):1129-1147
- CountryChina
- Language:English
-
Abstract:
New approaches to cancer immunotherapy have been developed, showing the ability to harness the immune system to treat and eliminate cancer. For many solid tumors, therapy with checkpoint inhibitors has shown promise. For hematologic malignancies, adoptive and engineered cell therapies are being widely developed, using cells such as T lymphocytes, as well as natural killer (NK) cells, dendritic cells, and potentially others. Among these adoptive cell therapies, the most active and advanced therapy involves chimeric antigen receptor (CAR)-T cells, which are T cells in which a chimeric antigen receptor is used to redirect specificity and allow T cell recognition, activation and killing of cancers, such as leukemia and lymphoma. Two autologous CAR-T products have been approved by several health authorities, starting with the U.S. Food and Drug Administration (FDA) in 2017. These products have shown powerful, inducing, long-lasting effects against B cell cancers in many cases. In distinction to the results seen in hematologic malignancies, the field of using CAR-T products against solid tumors is in its infancy. Targeting solid tumors and trafficking CAR-T cells into an immunosuppressive microenvironment are both significant challenges. The goal of this review is to summarize some of the most recent aspects of CAR-T cell design and manufacturing that have led to successes in hematological malignancies, allowing the reader to appreciate the barriers that must be overcome to extend CAR-T therapies to solid tumors successfully.
